期刊
JOURNAL OF CLINICAL MEDICINE
卷 8, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/jcm8122169
关键词
acute severe ulcerative colitis; infliximab; cyclosporine; tacrolimus; corticosteroids; surgical management
资金
- McGill CAS Research Support Program
- Kimberly Sue McCall Award in IBD Research
- Nesbitt-McMaster Award
Acute severe ulcerative colitis (ASUC) is a medical emergency which occurs in about 20%-30% of patients with ulcerative colitis during their lifetime, and does carry a mortality risk of 1%. The management of inflammatory bowel diseases has evolved with changes in objective patient monitoring, as well as the availability of new treatment options with the development of new biological and small molecules; however, data is limited regarding their use in the context of ASUC. This review aims to discuss the emerging data regarding biologicals and small molecules therapies in the context of ASUC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据